menu
    • menu
    [{"orgOrder":0,"company":"Sentynl Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Fosdenopterin","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Sentynl Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sentynl Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sentynl Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sentynl Therapeutics","sponsor":"Eiger BioPharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Lonafarnib","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Sentynl Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sentynl Therapeutics \/ Sentynl Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Sentynl Therapeutics \/ Sentynl Therapeutics"},{"orgOrder":0,"company":"Sentynl Therapeutics","sponsor":"Fortress Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Copper Histidine","moa":"ATP7A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sentynl Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sentynl Therapeutics \/ Fortress Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Sentynl Therapeutics \/ Fortress Biotech"}]

    Find Clinical Drug Pipeline Developments & Deals by Sentynl Therapeutics

    Menu

    Sentynl Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sentynl Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Sentynl Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Copper Histidine

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Fortress Biotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sentynl Therapeutics Announces FDA Acceptance of CUTX-101 for Menkes Disease

                            Details : CUTX-101 is a subcutaneous injectable formulation of copper histidinate, which is being evaluated for the treatment of menkes disease.

                            Product Name : CUTX-101

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 06, 2025

                            Lead Product(s) : Copper Histidine

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Fortress Biotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sentynl Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Sentynl Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lonafarnib

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Recipient : Eiger BioPharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Sentynl Acquires Zokinvy® for Hutchinson-Gilford Progeria Syndrome

                            Details : Sentynl will commercialize Zokinvy (lonafarnib) globally, the first FDA-approved treatment targeting progeria symptoms.

                            Product Name : Zokinvy

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 03, 2024

                            Lead Product(s) : Lonafarnib

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Recipient : Eiger BioPharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sentynl Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Sentynl Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fosdenopterin

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sentynl Receives MHRA Authorization for NULIBRY® in MoCD Type A

                            Details : Nulibry (fosdenopterin) is the first therapy for patients in Great Britain with molybdenum cofactor deficiency Type A, an ultra-rare genetic disorder that often progresses rapidly in infants.

                            Product Name : Nulibry

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 16, 2024

                            Lead Product(s) : Fosdenopterin

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth